%0 Journal Article
%A Pham, Thu-Thi
%A Nimptsch, Katharina
%A Aleksandrova, Krasimira
%A Jenab, Mazda
%A Reichmann, Robin
%A Wu, Kana
%A Tjønneland, Anne
%A Kyrø, Cecilie
%A Schulze, Matthias B
%A Kaaks, Rudolf
%A Katzke, Verena
%A Palli, Domenico
%A Pasanisi, Fabrizio
%A Ricceri, Fulvio
%A Tumino, Rosario
%A Krogh, Vittorio
%A Roodhart, Jeanine
%A Castilla, Jesús
%A Sanchez-Perez, Maria-Jose
%A Colorado-Yohar, Sandra Milena
%A Harbs, Justin
%A Rutegård, Martin
%A Papier, Keren
%A Aglago, Elom K
%A Dimou, Niki
%A Mayen-Chacon, Ana-Lucia
%A Weiderpass, Elisabete
%A Pischon, Tobias
%T Pre-Diagnostic Circulating Resistin Concentrations Are Not Associated with Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition Study.
%D 2022
%@ 2072-6694
%U http://hdl.handle.net/10668/20927
%X Resistin is a polypeptide implicated in inflammatory processes, and as such could be linked to colorectal carcinogenesis. In case-control studies, higher resistin levels have been found in colorectal cancer (CRC) patients compared to healthy individuals. However, evidence for the association between pre-diagnostic resistin and CRC risk is scarce. We investigated pre-diagnostic resistin concentrations and CRC risk within the European Prospective Investigation into Cancer and Nutrition using a nested case-control study among 1293 incident CRC-diagnosed cases and 1293 incidence density-matched controls. Conditional logistic regression models controlled for matching factors (age, sex, study center, fasting status, and women-related factors in women) and potential confounders (education, dietary and lifestyle factors, body mass index (BMI), BMI-adjusted waist circumference residuals) were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for CRC. Higher circulating resistin concentrations were not associated with CRC (RR per doubling resistin, 1.11; 95% CI 0.94-1.30; p = 0.22). There were also no associations with CRC subgroups defined by tumor subsite or sex. However, resistin was marginally associated with a higher CRC risk among participants followed-up maximally two years, but not among those followed-up after more than two years. We observed no substantial correlation between baseline circulating resistin concentrations and adiposity measures (BMI, waist circumference), adipokines (adiponectin, leptin), or metabolic and inflammatory biomarkers (C-reactive protein, C-peptide, high-density lipoprotein cholesterol, reactive oxygen metabolites) among controls. In this large-scale prospective cohort, there was little evidence of an association between baseline circulating resistin concentrations and CRC risk in European men and women.
%K colorectal cancer
%K inflammation
%K pre-diagnostic resistin
%K prospective
%K risk
%~